The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling. - Marr, Alexander R.; Halpin, Madeline; Corbin, Dominique L.; Asemelash, Yerdanos; Sher, Steven; Gordon, Britten K.; Whipp, Ethan C.; Mitchell, Shaneice; Harrington, Bonnie K.; Orwick, Shelley; Benrashid, Samon; Goettl, Virginia M.; et al. (Experimental Hematology & Oncology, 2024)